细胞培养四价流感疫苗在婴幼儿中的3期随机对照试验
这项3期多国观察者盲法随机对照试验在6-47月龄婴幼儿中比较细胞培养四价流感疫苗(QIVc)与MenC疫苗,共纳入5723人。
要点
- 未发现与QIVc相关的严重不良事件,多数征集性不良反应为轻中度。
核心结论
- QIVc在6-47月龄婴幼儿中显示出对流感的确切保护效力,且安全性临床可接受。
研究设计与样本
- 3期多国观察者盲法随机对照试验,在15个国家75个中心开展,纳入6-47月龄婴幼儿。
- 有流感疫苗接种史者接种1剂,无接种史者QIVc组第29天接种第2剂QIVc,MenC组第29天接种生理盐水安慰剂。
- 主要效力终点为末次接种后>14天至流感季结束的首发RT-PCR或培养确诊的抗原相似流感。
主要发现
- 未发现与QIVc相关的严重不良事件;1例社区获得性肺炎严重不良事件被研究者认为可能与MenC疫苗有关。
- 多数征集性不良反应为轻中度;研究期间报告3例死亡,均认为与 study 疫苗无关。
临床怎么用
- QIVc可为6-47月龄婴幼儿提供针对流感的有临床意义的保护,支持在该儿科人群中使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The burden of influenza is high in children younger than 5 years, and vaccination is an effective strategy to reduce disease. We aimed to evaluate the efficacy and immunogenicity of a cell culture-derived quadrivalent inactivated influenza vaccine (QIVc), as well as its safety and tolerability, in infants and young children. METHODS: This phase 3, multinational, observer-blind, randomised controlled trial was conducted at 75 sites across 15 countries. Enrolled infants and children aged 6-47 months were randomly assigned (1:1) to receive QIVc containing 15 μg haemagglutinin from the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains or comparator MenC containing 10 μg of meningococcal group C polysaccharide conjugated to tetanus toxoid. Randomisation was done centrally by an interactive response technology system. Study staff administering vaccine were unmasked because the vaccines differed in physical appearance, whereas study participants, their parents or legally authorised representatives, and the study personnel responsible for efficacy, safety, and immunogenicity assessments were masked to the group assignment. QIVc and MenC groups followed the same vaccination schedule. Participants with an influenza vaccination history received one dose of QIVc or MenC on day 1. Participants in the QIVc group with no influenza vaccination history received a second QIVc dose on day 29 whereas participants in the MenC group with no influenza vaccination history received a placebo vaccine (saline) on day 29. To monitor for protocol-defined influenza-like illness and safety, participants were followed up via weekly telephone calls or scheduled clinic visits for at least 180 days after last vaccination. The primary efficacy endpoint was absolute vaccine efficacy against first-occurrence influenza more than 14 days after the last vaccination and until the end of the influenza season. Absolute vaccine efficacy was defined as the relative reduction in influenza infection rate in the QIVc group relative to the MenC group and based on first-occurrence RT-PCR-confirmed or culture-confirmed influenza antigenically similar to seasonal vaccine strain. Time-to-event methodology based on a proportional hazard model was used for efficacy analyses that included all participants who received at least one dose of study vaccine. The primary objective of efficacy was demonstrated if the lower limit of the two-sided (interim analysis-adjusted) 97·5% CI of vaccine efficacy was greater than 0%. Safety was evaluated in all participants randomly assigned and vaccinated and who provided at least one post-vaccination safety observation. Safety endpoints included the percentage of participants with solicited local and systemic AEs. The study is registered at ClinicalTrials.gov (NCT03932682) and EudraCT (2018-001857-29), and the study is complete. FINDINGS: Between May 13, 2019, and June 2, 2023, 5723 infants and children (2751 [48·1%] female; 2972 [51·9%] male; mean age 25·9 months [SD 11·9]) were randomly assigned to the QIVc group (n=2860) and MenC group (n=2863). 26 participants did not receive any vaccine, and six participants withdrew before the start of the surveillance period. First occurrence of RT-PCR-confirmed influenza occurred in 104 (3·6%) of 2856 participants in the QIVc group and 173 (6·1%) of 2835 participants in the MenC group; absolute vaccine efficacy was 41·3% (97·98% CI 21·6-56·0). First occurrence of culture-confirmed antigenically similar influenza occurred in 44 (1·5%) of 2856 participants in the QIVc group and 82 (2·9%) of 2835 participants in the MenC group; absolute vaccine efficacy was 46·9% (97·5% CI 19·2-65·1). No serious adverse events were deemed related to QIVc, and one serious adverse event of community-acquired pneumonia was deemed possibly related to the MenC vaccine by the investigator. Most solicited adverse reactions were mild or moderate in severity. Three deaths were reported during the study, none of which were deemed related to study vaccines. INTERPRETATION: The primary objective of efficacy was demonstrated for both first-occurrence RT-PCR-confirmed and first-occurrence culture-confirmed, antigenically similar influenza following an influenza-like illness more than 14 days after last vaccination. QIVc thus provided protection against influenza and had a clinically acceptable safety profile, supporting the benefit of QIVc in this paediatric population. FUNDING: Seqirus UK.
引用
- Põder A, Ong-Lim AL, Rivera Medina DM, et al. Efficacy, immunogenicity, and safety of a cell culture-derived quadrivalent influenza vaccine compared with a non-influenza vaccine in infants and children across five influenza seasons: a phase 3, multinational, observer-blind, randomised controlled trial. Lancet Child Adolesc Health. 2026. PMID: 41962984. doi:10.1016/S2352-4642(26)00009-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。